国际眼科杂志(英文版)(International Journal of Ophthalmology)(国际刊号)

国际眼科杂志(英文版)(International Journal of Ophthalmology)(国际刊号) 知网目次维普目次

  • 高T3
基本信息
  • 主管单位:

    陕西省卫生健康委员会

  • 主办单位:

    中华医学会西安分会

  • 国际刊号:

    2222-3959;EISSN 2227-4898

  • 国内刊号:

  • 学科分类:

    五官科学

  • 字数:

    4000-26000

  • 有无基金:

    /有基金 100.0%

  • 周期:

    国际号刊-月刊

  • 特殊属性:

    外文期刊

联系信息
  • 电话:

    029-82210956;029-82245172(202404期)

  • 邮箱:

    ijopress@163.com;ijo2000@126.com(202404期)

  • 复合因子:

    0

  • 综合因子:

    0

  • 收录:

    知网目次,维普目次

  • 级别:

    高T3

期刊简介

《国际眼科杂志(英文版)(International Journal of Ophthalmology)(国际刊号)》期刊已被查看:

更新频次

高频栏目:

Basic Research-100%-期平均发文量4篇
Clinical Research-100%-期平均发文量13篇
Investigation-83.3%-期平均发文量1篇
Review Article-83.3%-期平均发文量1篇
Letter to the Editor-83.3%-期平均发文量2篇
Intelligent Ophthalmology-83.3%-期平均发文量2篇

中频栏目:

Brief Report-50.0%-期平均发文量1篇
Meta-Analysis-33.3%-期平均发文量1篇
Bibliometric Research-33.3%-期平均发文量1篇

低频栏目:

2024年02期其他-16.7%-期平均发文量2篇
2024年01期其他-16.7%-期平均发文量2篇
2023年12期其他-16.7%-期平均发文量3篇
2023年11期其他-16.7%-期平均发文量2篇
2023年10期其他-16.7%-期平均发文量3篇
Editorial-16.7%-期平均发文量1篇
2023年09期其他-16.7%-期平均发文量3篇

单位占比

其他-100.0%

一作占比

/有基金-100.0%

投稿指南

1、该刊只有国际刊号!

2、投稿方式:在线投稿。

3、刊内网址:http://www.ijo.cn(202404期)

4、投稿系统:https://mc03.manuscriptcentral.com/ijo

5、刊内邮箱:ijopress@163.com

ijo2000@126.com

6、刊内电话:029-82210956;029-82245172

7、出刊日期:月刊,每月18日出版。

2024年4月18日星期四

投稿须知【官网信息】

Instructions for Authors

GENERAL INFORMATION

International Journal of Ophthalmology—IJO, published continuously since 2008, a global ophthalmological scientific publication and a peer-reviewed, open access periodical published in print and online monthly (ISSN: 2222-3959 print, ISSN: 2227-4898 online). IJO is sponsored by the Chinese Medical Association Xi’an Branch, China and obtains guidance, and support from World Health Organization (WHO) and International Council of Ophthalmology (ICO). It is indexed in SCI Expanded, PubMed, PubMed Central, Chemical Abstract, Scopus, EMBASE etc. The latest JCR IF is 1.779. CiteScore in 2020 is 2.5.

Aim & Scope IJO is a comprehensive journal on ophthalmology accepting contributions in English from all over the world. These contributions mainly include original and review articles, both basic and clinical scientific manuscript. With more than 1000 manuscripts received annually, IJO accepts about 26% submitted manuscripts. IJO applies itself to establish a leading ophthalmology journal in the world, to provide a platform for ophthalmologists and impulse the advanced development of ophthalmology.

Manuscript Types  Original Articles (Basic Research and Clinical Research), Review, Meta-Analysis, Commentary, Investigation, Perspective, Opinion, Brief Report, and Letter to the Editor, etc.

Note: Submissions must be an original contribution not previously published (except as an abstract), must not currently be under consideration for publication elsewhere in the similar form, in any language, including both paper and electronic formats.

EDITORIAL POLICIES

Peer Review  All manuscripts are subjected to double blind peer-review and editorial approval before accepting for publication. All contributions will be sent to at least three or more independent reviewers, selected by the editors. Authors are welcome to suggest suitable independent reviewers and may also request that the journal excludes one or two individuals or laboratories, but the editor’s decision on the choice of referees is final. Editors, authors, and reviewers are required to keep confidential all details of the editorial and peer review process on submitted manuscripts, the peer review process is confidential and conducted anonymously; Outcomes of the review process include acceptance, acceptance with revisions but without re-review, revise and resubmit, or rejection. Results of the review process are normally available in about 2-4 months of submission.

Ethical Approval of Studies and Informed Consent  For all manuscripts reporting data from studies involving human participants or animals, a formal review and approval, or formal review and waiver by an appropriate institutional review board or ethics committee is required, and should be described in the Ethical Approval part at the beginning of the Subjects and Methods section. For investigators who do not have a formal ethics review committee (institutional or regional), the principles outlined in the Declaration of Helsinki (as revised in 2013) must be followed. For investigations done in humans, the Methods section must state the manner in which informed consent was obtained from the subjects (i.e., oral, or written), and whether participants received a stipend. If experimental animals were used in the research, IJO requires that authors confirm adherence to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research in the Methods section of their manuscript.

Clinical Trial Registry  When publishing clinical studies, IJO aims to comply with the Recommendations of International Committee of Medical Journal Editors (ICMJE) on trials registration ((http://www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal). Therefore, authors are requested to register the clinical trial presented in the manuscript in a public trial registry, and include the trial registration number in the Methods Section.

Conflicts of Interest A conflict of interest may exist when an author (or the author’s institution or employer) has financial, or personal relationships that could inappropriately influence (or bias) the author’s decisions, work, or manuscript. All authors are required to disclose potential conflicts of interest in the Acknowledgments section of the manuscript by following the Recommendations of the International Committee of Medical Journal Editors (ICMJE) http://www.icmje.org/urm_main.html

……

更多详情:

http://www.ijo.cn/gjyken/ch/first_menu.aspx?parent_id=20120104164955001


中国全科医学发文选摘

  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析

常见问题

  • 哪些期刊可以用来评职称?

    1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。

  • 你们的服务可以保证文章被发表吗?

    期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。

  • 请问发表一篇期刊的费用是多少?

    期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。

  • 如果发表不成功可以退款吗?

    如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。

  • 请问文章发表需要多长时间?

    不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。

  • 期刊发表能加急见刊吗?

    为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。